0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Low Doses of Interferon-α Are as Effective as Higher Doses in Inducing Remissions and Prolonging Survival in Chronic Myeloid Leukemia

Jill R. Schofield, BS; William A. Robinson, MD, PhD; James R. Murphy, PhD; and Douglas K. Rovira, MD
[+] Article and Author Information

From the University of Colorado Health Sciences Center, Denver, Colorado. Requests for Reprints: William A. Robinson, MD, PhD, University of Colorado Health Sciences Center, Division of Medical Oncology, Box B171, 4200 East Ninth Avenue, Denver, CO 80262. Acknowledgments: The authors thank Mrs. Kathie Baca for assistance with manuscript preparation and the Schering Corporation and Hoffman La Roche, Inc., for providing the interferon-α.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1994;121(10):736-744. doi:10.7326/0003-4819-121-10-199411150-00002
Text Size: A A A

Objective: To determine the toxicity and efficacy of low-dose interferon-α therapy in inducing remissions and prolonging survival in patients with chronic myeloid leukemia.

Design: Phase II evaluation and comparison with historical control patients and other series in which the investigators used higher interferon-α doses.

Setting: Tertiary care leukemia research clinic.

Patients: 41 patients with newly diagnosed or previously treated chronic-phase, Philadelphia chromosome-positive chronic myeloid leukemia received interferon-α at a dose of 2 × 106 U/m2 body surface area daily for 28 days and then three times weekly.

Measurements: Complete blood counts and physical examinations were done monthly to determine hematologic remission and toxicity. To determine karyotypic response, bone marrow cytogenetic analyses were done at 6 monthly intervals in patients who achieved a complete hematologic remission. In addition, Kaplan-Meier survival curves and median survival values were generated from diagnosis and the start of therapy with interferon-α.

Results: 70% of patients treated with low-dose interferon-α within 1 year of diagnosis achieved a complete hematologic remission, and 22% of these patients had a major or complete karyotypic response. Investigators who used higher interferon-α doses in similar patient populations have reported complete hematologic remission rates of 59% to 70% and major and complete cytogenetic response rates of 16% to 29%. The Kaplan-Meier estimated 5-year survival rate of minimally pretreated patients in our study is 73% (95% CI, 51% to 95%), which compares favorably with survivals reported by investigators who used higher doses. The estimated yearly cost of the interferon-α used in our study is $5953 compared with a median of $24 375 for the higher doses used by other investigators. Less toxicity was also observed.

Conclusion: Low-dose interferon-α is as effective as higher-dose interferon-α in inducing remissions and prolonging survival in patients with chronic myeloid leukemia but is considerably less expensive and toxic.

Figures

Grahic Jump Location
Figure 1.
The Kaplan-Meier survival curves shown from the time of diagnosis (dotted line) and from the start of interferon therapy (broken line) for 41 patients with chronic-phase chronic myeloid leukemia treated with low-dose interferon-α compared with the actuarial survival from the diagnosis of 122 control patients treated with hydroxyurea (solid line).

IFN α = interferon-α.

Grahic Jump Location
Grahic Jump Location
Figure 2.
The Kaplan-Meier survival curves for 27 patients with chronic myeloid leukemia treated with interferon-α within 1 year of diagnosis (broken line) compared with that of 14 patients who started interferon therapy more than 1 year after diagnosis (dotted line).

Survival is shown from the start of interferon therapy. IFN α = interferon-α.

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)